Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
about
Osteoclasts are active in bone forming metastases of prostate cancer patientsTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerOsteoprotegerin in bone metastases: mathematical solution to the puzzleRunx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.Rapid ex vivo imaging of PAIII prostate to bone tumor with SWIFT-MRIBone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.Cancer of the prostate presenting with diffuse osteolytic metastatic bone lesions: a case reportAn integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.Positron emission tomography/computerized tomography in lung cancer.Gene targeting to the stroma of the prostate and bone.Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition.Prostate cancer regulatory networksOptimizing bone health and minimizing skeletal morbidity in men with prostate cancerOsteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.Nothing but skin and bone.The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsThe host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Estrogenic side effects of androgen deprivation therapy.Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteobA new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancerClinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortiumExtracellular molecules involved in cancer cell invasionInhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signalingAndrogen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer.Hyperglobus, do not forget the sinister.Cathepsin L targeting in cancer treatment.Current and emerging therapies for bone metastatic castration-resistant prostate cancer.Effects of calcium-sensing receptor on the secretion of parathyroid hormone-related peptide and its impact on humoral hypercalcemia of malignancy.Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagyProstate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.Bone and prostate cancer cell interactions in metastatic prostate cancer.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.
P2860
Q21090081-B9D647F0-ECE1-4B9E-9F39-B4D3A40E60D1Q26752785-CBBD02C0-6712-4AAD-ABE9-0A75FC2C124BQ27329714-7203296C-9AA9-465D-A107-97F707F8C954Q30435146-4F8B468F-E64B-49B0-B477-FC7CAABC0643Q30683446-46D1BC36-1EF0-49AB-BA9C-150CF7D92995Q30852837-1A583055-DCAC-4C3A-8235-9377978A9628Q33405009-76E83661-6F6F-4D3E-973A-61E67DFEE18EQ33620502-03BCCF5A-7B90-4F34-B90D-D76001AC1FEDQ33657999-FE7C6C1C-C939-42BC-AC7C-85489C4D227EQ33699188-FCCD7468-0501-4FE2-B794-490D49B17BEFQ33829463-39257E45-D560-4F11-B92A-CCA0FCC38F85Q33960568-BCA746CB-E6B3-4B8F-B3F5-99EBAED0B75CQ34023510-71773B3E-DEF7-4AF4-B9D8-80942F72BF3CQ34159609-7597BE64-1737-4763-8311-3DFEB8725DF2Q34309227-91A362BB-765A-449B-B96B-1D8664B42280Q34576635-D2D4737F-9311-4212-BB13-13997F4DB715Q34617864-B01D3C74-0617-44B5-9725-B6A5EBAFDAD1Q34699785-466C1F0C-5A56-4F05-B18B-2AA7B5129563Q34743239-A205D067-AF16-44CC-9186-242B0BC3C3FAQ34971654-E613FEF4-9174-4C01-B96D-B75ACB4299E6Q34999463-4C872501-A23E-4E29-B67B-BD6DD24B2625Q35003674-C22A0645-95BB-42BE-B75C-E113C97C1F7CQ35060303-4EA620EE-F21A-4805-BA2F-63E361BE34E6Q35218871-F5766616-51CA-44C8-9773-51EC90901C02Q35237503-B546718A-8CB8-4B3C-8CFE-B7E73C95B8F5Q35540734-4CD6F155-6698-49DF-A72B-E7C133C2144EQ35570431-B86F13E2-4340-425F-818B-1C3CC8F50300Q35609965-245279AA-E151-402B-ADA5-583A5205ED67Q35751362-C3CDF0FB-93B5-42FB-87F0-A636CD39D41EQ35774987-14603804-8ED4-435A-9303-44C94777817EQ35855547-DDFB815D-7BFD-4E7C-B6FC-A5EC1FA29153Q35855577-3AA43626-64FD-4305-8CBF-C3F2D7C2F745Q35978911-F4D7F62A-C467-4429-B7CA-2946E7BA5F91Q36218199-0CB56D9F-EAE9-4F25-A808-2B6C08CA0F64Q36358303-2A3A7145-01AE-4C30-BA3C-91AF2DB05E81Q36444286-02194237-8AA4-4EF2-B1CA-85009D1398A4Q36557246-4A3DB69E-C10F-41C6-864B-3B5031768061Q36640228-A4EC0BBA-4F3F-4F86-8A70-621755BF725FQ36682278-75DEBA83-A701-4AB3-AEF4-A64693A147E9Q36759374-72F11FC1-DFDE-4C74-8F11-BC1F0870EEFE
P2860
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
@ast
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
@en
type
label
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
@ast
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
@en
prefLabel
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
@ast
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
@en
P2860
P356
P1476
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
@en
P2093
Evan T Keller
Julie Brown
P2860
P304
P356
10.1002/JCB.10662
P577
2004-03-01T00:00:00Z